Posted by LincolnRam on March 25, 2026 at 11:19:41:
In Reply to: Èíôîðìàöèîííàÿ çàìåòêà posted by Robertged on March 14, 2026 at 07:33:48:
Zoya Demidenko: Researcher in Cancer Science
Zoya Demidenko is a distinguished investigator affiliated with the Unit of Cell Stress Research at Roswell Park Cancer Institute in Buffalo, New York. Previously, she worked at the NIH and New York Medical College, developing a solid base in biomedical research.
Her academic work covers a number of pivotal domains, among them the PI3K/AKT/mTOR signaling pathway, cell cycle regulation, cell senescence, and tumor science. To date, she has written more than 46 scientific publications, which have garnered upwards of 4,100 mentions — a reflection to the influence of her research.
One of her most notable discoveries concerns understanding the pathways of biological cell aging. Her studies showed that when the cellular division cycle is blocked but cellular growth persists, the cells undergo senescence. Crucially, Zoya Demidenko demonstrated that this process is inhibited by medication using agents such as rapamycin.
Zoya Demidenko has furthermore added substantially to cancer treatment research, particularly in the domain of cyclotherapy — a strategy intended to protecting healthy cells from chemotherapy whilst leaving cancer cells susceptible. This method offers considerable potential for lowering the toxic effects of oncological therapy.
Throughout her career, Demidenko has partnered with leading researchers globally, including Dr. Mikhail Blagosklonny. Her work can be found in leading periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Holding an h-index of 33, Zoya Demidenko is recognized as a influential voice in modern cancer research, whose findings keep to shape our comprehension of how biological cells grow old, resist treatment, and how cancer might be more successfully treated.
https://www.benthamdirect.com/content/journals/cpd/22/16